Annexon, Inc.
ANNXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$216.4M | −$154.1M | −$143.7M | −$145.6M | −$130.7M | −$63.5M |
| Net income | −$206.7M | −$138.2M | −$134.2M | −$141.9M | −$130.3M | −$63.4M |
| Total assets | $277.6M | $350.1M | $297.7M | $285.1M | $287.0M | $355.9M |
| Total liabilities | $65.9M | $57.0M | $47.1M | $53.9M | $55.1M | $11.7M |
| Equity | $211.6M | $293.1M | $250.6M | $231.2M | $231.9M | $344.3M |
| EPS (diluted) | $-1.34 | $-1.01 | $-1.77 | $-2.60 | $-3.40 | — |
| Shares out. | 149.4M | 109.4M | 78.4M | 38.6M | 38.2M | 38.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −97.7%
- Return on assets
- −74.5%
- Return on capital (ROCE)
- −92.1%
- Liabilities / assets
- 23.7%
- Debt / equity
- 0.31×
- Book value / share
- $1.42
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -7.93distress
- Accruals / assets
- −7.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-10-31A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
- Phase 3Recruitingreadout ~2026-12-31An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Biotechnology Value Fund L PPassive (13G)May 15, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Redmile Group, LlcPassive (13G)Feb 17, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Blackrock, Inc.Passive (13G)Jan 21, 2026
- Satter Muneer AActivist (13D)Nov 21, 2025
- Logos Global Management LpPassive (13G)Aug 14, 2025
- Point72 Asset Management, L.P.Passive (13G)May 15, 2025
- Bain Capital Life Sciences Fund, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 24.3M | 13.3 | +3.6% |
| Apr 30, 2026 | 23.4M | 10.9 | +19.1% |
| Apr 15, 2026 | 19.7M | 7.9 | +5.6% |
| Mar 31, 2026 | 18.6M | 5.7 | +13.6% |
| Mar 13, 2026 | 16.4M | 6.1 | +3.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Results of operationsMar 30, 2026
- Director / officer changeFeb 17, 2026
- Regulation FD disclosureJan 14, 2026
- Other material eventJan 12, 2026
- Entered a material agreement · Other material eventNov 14, 2025
- Results of operationsNov 10, 2025
- Results of operationsAug 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.